Results 211 to 220 of about 12,579 (242)

Development of Modified Vaccinia Virus Ankara-based Influenza Vaccines

, 2018
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Protective efficacy of Modified Vaccinia virus Ankara in preclinical studies

Vaccine, 2013
Modified Vaccinia virus Ankara (MVA) is a tissue culture-derived, highly attenuated strain of vaccinia virus (VACV) exhibiting characteristic defective replication in cells from mammalian hosts. In the 1960s MVA was originally generated as a candidate virus for safer vaccination against smallpox.
Asisa Volz, Gerd Sutter
openaire   +2 more sources

Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques

Vaccine, 2001
Modified vaccinia virus Ankara (MVA)-based recombinant viruses have been shown to be potent vaccine candidates for several infectious and neoplastic diseases. Since a major application of these live, replication-deficient vectors would be their use in immunocompromised or potentially immunocompromised individuals, a preclinical safety study was carried
Stittelaar, Koert, Kuiken, Thijs, de Swart, Rik, Amerongen, Geert, Vos, HW, Niesters, HGM, Schalkwijk, Pim, Kwast, Theodorus, Wyatt, LS, Moss, B, Osterhaus, Ab   +10 more
openaire   +2 more sources

Vaccinia Vectors as Candidate Vaccines: The Development of Modified Vaccinia Virus Ankara for Antigen Delivery

Current Drug Target -Infectious Disorders, 2003
Vaccinia viruses engineered to express foreign genes are powerful vectors for production of recombinant proteins. Originating from highly efficacious vaccines securing world-wide eradication of smallpox, the most appealing use of vaccinia vectors is to serve as vaccine delivery system for heterologous antigens.
Gerd, Sutter, Caroline, Staib
openaire   +2 more sources

Substitution of Vaccinia Virus Elstree by Modified Vaccinia Virus Ankara to test the Virucidal Efficacy of Chemical Disinfectants

Zoonoses and Public Health, 2008
SummaryAfter the eradication of variola in 1980, the smallpox vaccination was considered to be no longer required and was subsequently abandoned mainly because of possible adverse effects of vaccinia virus especially in first‐time vaccinees. Despite a growing number of humans without immunity against vaccinia virus, vaccinia virus Lister Elstree (VACV)
S, Hartnack, S, Essbauer, U, Truyen
openaire   +2 more sources

Modified Vaccinia Virus Ankara (MVA) based Vaccines – Immunostimulatory and Protective Capacity

2010
Modified vaccinia virus Ankara (MVA) is a highly attenuated and replication-deficient vaccinia virus (VACV) which serves as promising candidate replacement vaccine against smallpox. Moreover, genetically modified MVA viruses are investigated as vector vaccines against various infectious diseases and cancer.
Michael H. Lehmann, Melanie Kremer, Yasemin Suezer, Gerd Sutter   +3 more
openaire   +1 more source

Generation and Production of Modified Vaccinia Virus Ankara (MVA) as a Vaccine Vector

2017
The smallpox vaccine based on the vaccinia virus was successfully used to eradicate smallpox, but although very effective, it was a very reactogenic vaccine and responsible for the deaths of one to two people per million vaccinated. Modified Vaccinia virus Ankara (MVA) is an attenuated derivative, also used in the smallpox eradication campaign and now ...
Vincent, Pavot, Sarah, Sebastian, Alison V, Turner, Jake, Matthews, Sarah C, Gilbert   +4 more
openaire   +2 more sources

Human Mpox Virus Infection After Receipt of Modified Vaccinia Ankara Vaccine

JAMA, 2023
openaire   +2 more sources

Cervical cancer prevention and control in women living with human immunodeficiency virus

Ca-A Cancer Journal for Clinicians, 2021
Philip E Castle, Vikrant V Sahasrabuddhe
exaly  

Current treatment and recent progress in gastric cancer

Ca-A Cancer Journal for Clinicians, 2021
Smita S Joshi, Brian D Badgwell
exaly